NEW YORK, NY / ACCESSWIRE / March 19, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
Activision Blizzard, Inc. (ATVI)
Class Period: August 2, 2018 - January 10, 2019
Lead Plaintiff Deadline: March 19, 2019
Join the action: https://www.zlk.com/pslra-1/activision-blizzard-inc-loss-form?wire=3
The lawsuit alleges: Activision Blizzard, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (i) the termination of Activision Blizzard and Bungie's partnership, giving Bungie full publishing rights and responsibilities for the Destiny franchise, was imminent; (ii) the termination of the two companies' relationship would foreseeably have a significant negative impact on Activision Blizzard's revenues; and (iii) as a result, Activision Blizzard's public statements were materially false and misleading at all relevant times.
To learn more about the Activision Blizzard, Inc. class action contact firstname.lastname@example.org.
Corcept Therapeutics Incorporated (CORT)
Class Period: August 2, 2017 - February 5, 2019
Lead Plaintiff Deadline: May 13, 2019
Join the action: https://www.zlk.com/pslra-1/corcept-therapeutics-incorporated-loss-form?wire=3
The lawsuit alleges: Corcept Therapeutics Incorporated made materially false and/or misleading statements and/or failed to disclose that: (1) the Company had improperly paid doctors to promote its drug Korlym; (2) the Company aggressively promoted Korlym for off-label uses; (3) the Company's sole specialty pharmacy was a related party; (4) the Company artificially inflated its revenue and sales using illicit sales practices through a related party; (5) such practices are reasonably likely to lead to regulatory scrutiny; and (6) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
To learn more about the Corcept Therapeutics Incorporated class action contact email@example.com.
U.S. Xpress Enterprises, Inc. (USX)
Class Period: Purchasers of common stock pursuant/and or traceable to the initial public offering completed in June 2018
Lead Plaintiff Deadline: May 10, 2019
Join the action: https://www.zlk.com/pslra-1/u-s-xpress-enterprises-inc-loss-form-2?wire=3
The complaint alleges that the Offering Documents failed to disclose that: (1) a shortage of trucks was negatively impacting U.S. Xpress's dedicated division; (2) (a) certain shipping patterns had been performing differently than expected and, as a result, (b) utilization and driver retention and hiring were being negatively affected, and as a result, (c) U.S. Xpress's dedicated accounts, including one large account, were being negatively impacted; and as a result, (d) U.S. Xpress's OTR division was providing continued support to the dedicated division; (3) (a) U.S. Xpress failed to stay informed regarding two large liability events; and as a result (b) U.S. Xpress's insurance claim expense was understated; and (4) U.S. Xpress's cost per mile for driver wages and independent contractors was exceeding the Company's internal expectations.
To learn more about the U.S. Xpress Enterprises, Inc. class action contact firstname.lastname@example.org.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LL
View source version on accesswire.com: